Adage Capital Partners Gp, L.L.C. Arcellx, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $54.6 Billion
- Q3 2024
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Arcellx, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 292,009 shares of ACLX stock, worth $18.4 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
292,009
Previous 323,468
9.73%
Holding current value
$18.4 Million
Previous $17.9 Million
36.6%
% of portfolio
0.04%
Previous 0.03%
Shares
10 transactions
Others Institutions Holding ACLX
# of Institutions
205Shares Held
44.1MCall Options Held
2.23MPut Options Held
907K-
Paradigm Biocapital Advisors LP New York, NY4MShares$252 Million12.04% of portfolio
-
Perceptive Advisors LLC New York, NY3.89MShares$245 Million8.48% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$236 Million23.89% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$222 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.46MShares$155 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $2.76B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...